Risk factor control is key in diabetic nephropathy

Practitioner

Volumn 258, Issue 1768, 2014, Pages 13-17

  Lewis, Gareth ^a   Maxwell, Alexander P ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; HEALTH; HUMAN; METHODOLOGY; MORBIDITY; RISK FACTOR; RISK MANAGEMENT;

DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; MORBIDITY; RISK FACTORS; RISK MANAGEMENT; WORLD HEALTH;

EID: 84896294282     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Chowdhury TA, Barnett AH, Bain SC. Pathogenesis of diabetic nephropathy. Trends Endocrinol Metab 1996;7:320-323
2. UK Renal Registry report 2012. www.renalreg.com/Report-Area/Report% 202013/01-Chap-01.pdf
3. Groop PH, Thomas MC, Moran JL et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
4. Suckling R, Gallagher H. Chronic kidney disease, diabetes mellitus and cardiovascular disease: risks and commonalities. J Ren Care 2012;38(Suppl 1):4-11
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-986
6. Gaede P, Lund-Anderson H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358(6):580-591
7. Holman RR, Paul SK, Bethel MA et al. 10-year followup of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-1589
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 12;317(7160):703-13
9. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137-188
10. Hill CJ, Fogarty DG. Changing trends in end-stage renal disease due to diabetes in the United Kingdom. J Ren Care 2012;38(Suppl 1):12-22
11. National Institute for Health and Clinical Excellence. Management of chronic kidney disease. NICE. London. 2008
12. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. http://www.kdigo.org/clinical-practice-guidelines/ pdf/CKD/KDIGO-2012-CKD-GL.pdf
13. Dean J. Organising care for people with diabetes and renal disease. J Ren Care 2012;38(Suppl 1):23-29
14. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).Kidney Int 2003;63(1):225-232
15. Ritz E. Clinical manifestations and natural history of diabetic kidney disease. Med Clin N Am 2013;97(1):19-29
16. Wu HY, Huang JW, Lin HJ et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ 2013;347:f6008
17. Hirst JA, Taylor KS, Stevens RJ et al. The impact of renin-angiotensin- aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 2012;81:674-683
18. Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80(3):282-287
19. Slagman MC, Waanders F, Hemmelder MH et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.BMJ 2011;343: d4366
20. Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med 2011;27(4):458-468
21. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892-1903
22. Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 2013 doi:10.1038/nrneph. 2013.251 (Epub ahead of print)
23. Koya D, Campese VM. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb 2013;20:407-424
24. Garg R, Williams ME. Diabetes management in the kidney patient. Med Clin N Am2013;97(1):135-156
25. Bowman BT, Kleiner A, Bolton WK. Comanagement of diabetic kidney disease by the primary care provider and nephrologist. Med Clin N Am 2013;97(1):157-173
26. Dreyer G, Hull S, Mathur R et al. Progression of chronic kidney disease in a multi-ethnic community cohort of patients with diabetes mellitus. Diabet Med 2013;30:956-963
27. Meran S, Don K, Shah N et al. Impact of chronic kidney disease management in primary care. Q J Med 2011;104:27-34
28. Jones RK, Hampton D, O'Sullivan DJ, Phillips A. Diabetes and renal disease: who does what? Clin Med 2013;13(5):460-464
29. Bramham K, Rajasingham D. Pregnancy in diabetes and kidney disease. J Ren Care 2012;38(Suppl 1):78-89
30. Tennant PW, Glinianaia SV, Bilous RW et al. Preexisting diabetes, maternal glycated haemoglobin, and the risks of fetal and infant death: a population-based study. Diabetologia 2014;57(2):285-294